Steep Hill, the global leader in cannabis science, genetics, research, testing, and analytics headquartered in Berkeley, California, announced plans this week to expand into the global cannabis market. In a press release from PRNewswire (1), Jmîchaeĺe Keller, the CEO and Chairman of the Board of Steep Hill, Inc., stated that the company will expand into Mexico and six new European Union markets offering full service cannabis quality assurance to those markets as they open and legalize cannabis.
According to the announcement, the licensee for Steep Hill Canada will expand their testing umbrella to include Steep Hill Mexico, Steep Hill Germany, Steep Hill Spain, Steep Hill France, Steep Hill Italy, Steep Hill Switzerland, and Steep Hill United Kingdom.
"I’m extremely pleased at the opportunity to partner with Steep Hill to bring safe cannabis and scientific integrity to emerging international markets,” Martin Shefsky, the CEO of Steep Hill Worldwide, said in the press release. “I anticipate that before long, full legalization will be implemented throughout the European Union and our presence will enable growers, producers, processors, and retailers to offer standardized tested cannabis for patients and consumers across the European Union, while also enabling us to create a platform to share scientific and technology developments throughout the global cannabis market. We are actively seeking operating partners with local market experience to join us in several of our strategic territories."
Keller also explained that in unregulated markets, Steep Hill wants to be on the ground supporting the legalization and regulatory process, and helping regulators avoid making the mistakes that other jurisdictions have made in the past. “We believe that our role as the industry standard, allows us to leverage our world-class scientific knowledge and state of the art technology to help regulators provide confidence in the marketplace that the cannabis patients consume is both safe and effective,” he said. “We look forward to collaborating closely with Martin and his group to strive for this gold standard, across all international borders."
For more information on Steep Hill, please visit www.steephill.com
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.